[go: up one dir, main page]

NO20092416L - Salter av 3-(3-amino-2-(R)-hydroksy-propyl)-1-(4-fluorfenyl)-8-(8-metylnaftalen-1-ylmetyl)-1,3,8-triaza-spiro[4,5]decan-4-on - Google Patents

Salter av 3-(3-amino-2-(R)-hydroksy-propyl)-1-(4-fluorfenyl)-8-(8-metylnaftalen-1-ylmetyl)-1,3,8-triaza-spiro[4,5]decan-4-on

Info

Publication number
NO20092416L
NO20092416L NO20092416A NO20092416A NO20092416L NO 20092416 L NO20092416 L NO 20092416L NO 20092416 A NO20092416 A NO 20092416A NO 20092416 A NO20092416 A NO 20092416A NO 20092416 L NO20092416 L NO 20092416L
Authority
NO
Norway
Prior art keywords
triaza
decan
ylmethyl
spiro
propyl
Prior art date
Application number
NO20092416A
Other languages
English (en)
Inventor
Frank J Villani
Steven J Mehrman
Armin Roessler
Roger Faessler
Jean Francois Alexandre Lucas Hegyi
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39145092&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20092416(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20092416L publication Critical patent/NO20092416L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Det beskrives salter av 3-(3-amino-2-(R)-hydroksy-propyl)-1-(4-fluor-fenyl-8-(8-metyl-naftalen-1-ylmetyl)-1,3,8-triaza-spiro[4.5]dekan-4-on. Det beskrives videre farmasøytiske preparater inneholdende disse samt deres anvendelse ved behandling av forstyrrelser og tilstander modulert av NOP, for eksempel depresjon, angst, alkoholmisbruk, osv. Det beskrives videre fremgangsmåter for fremstilling av 3-(3-amino-2-(R)-hydroksy-propyl)-1-(4-fluor-fényl])-8-(8-metyl-naftalen-l-ylmetyl)-1,3,8-triaza-spiro[4.5]dekan-4-on og dennes tilsvarende salter.
NO20092416A 2006-11-28 2009-06-24 Salter av 3-(3-amino-2-(R)-hydroksy-propyl)-1-(4-fluorfenyl)-8-(8-metylnaftalen-1-ylmetyl)-1,3,8-triaza-spiro[4,5]decan-4-on NO20092416L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86137806P 2006-11-28 2006-11-28
PCT/US2007/084642 WO2008067167A1 (en) 2006-11-28 2007-11-14 Salts of 3-(3-amino-2-(r)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one

Publications (1)

Publication Number Publication Date
NO20092416L true NO20092416L (no) 2009-08-21

Family

ID=39145092

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092416A NO20092416L (no) 2006-11-28 2009-06-24 Salter av 3-(3-amino-2-(R)-hydroksy-propyl)-1-(4-fluorfenyl)-8-(8-metylnaftalen-1-ylmetyl)-1,3,8-triaza-spiro[4,5]decan-4-on

Country Status (19)

Country Link
US (1) US8703948B2 (no)
EP (1) EP2102206B1 (no)
JP (1) JP5727139B2 (no)
KR (1) KR20090083954A (no)
CN (2) CN101622254B (no)
AR (1) AR063982A1 (no)
AU (1) AU2007325355A1 (no)
CA (1) CA2670858C (no)
CL (1) CL2007003406A1 (no)
CR (1) CR10898A (no)
EA (1) EA200970517A1 (no)
EC (1) ECSP099365A (no)
IL (1) IL198793A0 (no)
MX (1) MX2009005641A (no)
NO (1) NO20092416L (no)
PE (1) PE20081300A1 (no)
TW (1) TW200838862A (no)
UY (1) UY30746A1 (no)
WO (1) WO2008067167A1 (no)

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155699A (en) 1960-03-30 1964-11-03 Mobay Chemical Corp Purification of isocyanates by reduction of the hydrolyzable chlorine and acid content
US3161644A (en) 1962-06-22 1964-12-15 Res Lab Dr C Janssen N V 1-benzyl-4-substituted piperidines
US3155670A (en) 1962-06-22 1964-11-03 Res Lab Dr C Janssen N V 1-oxo-2, 4, 8, triaza-spiro (4, 5) decanes
US3238216A (en) 1963-06-20 1966-03-01 Res Lab Dr C Janssen N V Substituted 1, 3, 8-triaza-spiro (4, 5) decanes
US3839340A (en) 1968-09-27 1974-10-01 Fmc Corp Substituted 1,3,8-triazaspiro{8 4.5{9 decanes
US3629267A (en) 1968-10-28 1971-12-21 Smith Kline French Lab Benzoheterocyclicalkyl derivatives of 4-(2-keto -1-benzimidazolinyl)-piperidine 4-(2-keto - 1 - benzimidazolinyl) -1 2 3 6 tetrahydropyridine 1 - phenyl - 1 3 8-triazaspiro(4 5)decan - 4 - one and 2 4 9-triazaspiro(5 5)undecan-1 3 5-trione
US3859340A (en) 1970-09-09 1975-01-07 Squibb & Sons Inc ' -methylfluorene-2-acetic acid
US4020072A (en) 1976-05-04 1977-04-26 E. R. Squibb & Sons, Inc. 5-Aminomethyl-1H-pyrazolo[3,4-b]pyridines
JPS54109983A (en) * 1978-02-13 1979-08-29 Sumitomo Chem Co Ltd Novel spiroamine derivative and its preparation
US4329363A (en) 1978-09-08 1982-05-11 Merck & Co., Inc. Substituted mercapto acid amides and their use
US4526896A (en) 1978-12-26 1985-07-02 Riker Laboratories, Inc. Tetrazol-5-yl 2-nitro-3-phenylbenzofurans and antimicrobial use thereof
JPS57212180A (en) 1981-06-19 1982-12-27 Yoshitomi Pharmaceut Ind Ltd Tetrahydrofuran(thiophene) compound
WO1988000190A1 (en) 1986-06-25 1988-01-14 Massachusetts Institute Of Technology Optically active derivatives of glycidol
US5486362A (en) 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
DE4135473A1 (de) 1991-10-28 1993-04-29 Bayer Ag Triazaspirodecanon-methylchromane
JPH08500326A (ja) 1991-12-27 1996-01-16 ベス イスラエル ホスピタル アソシエイション 免疫抑制剤としてのスピペロンまたはスピペロン誘導体の使用
FR2708606B1 (fr) * 1993-07-30 1995-10-27 Sanofi Sa Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
CA2171446C (en) 1993-09-09 2004-11-23 Donald James Kyle Pseudo- and non-peptide bradykinin receptor antagonists
US5739336A (en) 1995-06-23 1998-04-14 Syntex (U.S.A.) Inc. 1,3,8-triaza- and 3,8-diaza-1-oxaspiro 4,5! decane derivatives
US5821219A (en) 1995-08-11 1998-10-13 Oregon Health Sciences University Opioid antagonists and methods of their use
SK113998A3 (en) 1996-03-29 2001-05-10 Pfizer 6-phenylpyridyl-2-amine derivatives
CA2226058C (en) 1997-01-30 2008-01-29 F. Hoffmann-La Roche Ag 8-substituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives
US6013652A (en) * 1997-12-04 2000-01-11 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin antagonists
SI0921125T1 (en) 1997-12-05 2002-04-30 F. Hoffmann-La Roche Ag 1,3,8-Triazaspiro(4,5)decan-4-on derivatives
PT921125E (pt) 1997-12-05 2002-06-28 Hoffmann La Roche Derivados de 1,38-triaza-espiro 4,5 decan-4-ona
US6277991B1 (en) 1998-05-18 2001-08-21 Novo Nordisk A/S 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes
JP2002515503A (ja) 1998-05-18 2002-05-28 ノボ ノルディスク アクティーゼルスカブ オピオイド受容体のサブタイプへの高い親和性を有する新規１，３，８−トリアザスピロ〔４，５〕デカノン
PT970957E (pt) 1998-06-12 2002-02-28 Hoffmann La Roche Derivados de diaza-espiro¬3,5|nonamo
AU4562799A (en) 1998-06-15 2000-01-05 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
ID29137A (id) 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
US6326379B1 (en) 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
ES2237047T3 (es) 1998-10-23 2005-07-16 Pfizer Inc. Compuestos de 1,3,8-triazaespiro(4,5)decanona como agonistas del receptor orl1.
BR9915475A (pt) 1998-11-20 2001-12-18 Smithkline Beecham Spa Derivados da quinolina-4-carboxamida comoantagonistas dos receptores de nk-3 e nk-2
JP2000169476A (ja) 1998-12-09 2000-06-20 Banyu Pharmaceut Co Ltd ４−オキソイミダゾリジン−５−スピロ−含窒素複素環式化合物
AU1382901A (en) 1999-11-17 2001-05-30 Novo Nordisk A/S Novel triazaspirodecanones with high affinity for opioid receptor subtypes
DE19956598A1 (de) 1999-11-25 2001-06-13 Bosch Gmbh Robert Ventil zum Steuern von Flüssigkeiten
JP3989247B2 (ja) 1999-12-06 2007-10-10 ユーロ−セルティーク エス．エイ． ノシセプチン受容体親和性を有するトリアゾスピロ化合物
JP2005231995A (ja) 1999-12-22 2005-09-02 Meiji Seika Kaisha Ltd オピオイドδ受容体アゴニスト／アンタゴニストとして有用なスピロ化合物
GB0003224D0 (en) 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
US6482829B2 (en) 2000-06-08 2002-11-19 Hoffmann-La Roche Inc. Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
WO2001096337A1 (en) 2000-06-14 2001-12-20 Banyu Pharmaceutical Co.,Ltd 4-oxoimidazolidine-2-spiro-nitrogenous heterocycle compounds
EP1392687B1 (en) 2001-04-10 2017-02-01 Janssen Pharmaceuticals, Inc. 1,3,8-triazaspiro[4,5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders
RU2299883C2 (ru) 2001-04-18 2007-05-27 Эро-Селтик, С.А. Соединения спиропиразола, содержащая их фармацевтическая композиция, способ модуляции опиоидного рецептора и способ лечения с применением таких соединений
US20030078278A1 (en) * 2001-06-26 2003-04-24 Pfizer Inc. Spiropiperidine compounds as ligands for ORL-1 receptor
JP4356453B2 (ja) 2001-07-23 2009-11-04 萬有製薬株式会社 ４−オキソイミダゾリジン−２−スピロピペリジン誘導体
US20040014955A1 (en) * 2001-12-17 2004-01-22 Carlos Zamudio Identification of essential genes of cryptococcus neoformans and methods of use
WO2003064425A1 (en) 2002-01-28 2003-08-07 Pfizer Japan Inc. N-substituted spiropiperidine compounds as ligands for orl-1 receptor
EP1601674B1 (en) * 2002-09-09 2012-08-08 Janssen Pharmaceutica NV Hydroxyalkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
NZ553202A (en) * 2004-08-19 2010-12-24 Vertex Pharma Modulators of muscarinic receptors
WO2006130416A2 (en) * 2005-06-02 2006-12-07 Janssen Pharmaceutica, N.V. Novel 3-spirocyclic indolyl derivatives useful as orl-1 receptor modulators
EP2101769B1 (en) 2006-11-28 2012-10-24 Janssen Pharmaceutica, N.V. Methods for the treatment of alcohol abuse, addiction and dependency
MX2009011006A (es) 2007-04-09 2009-11-02 Janssen Pharmaceutica Nv Derivados de 1,3,8-trisustituido-1,3,8-triaza-espiro[4.5]decano-4- ona como ligandos del receptor de orl-1 para el tratamiento de ansiedad y depresion.
US20100076003A1 (en) 2008-09-19 2010-03-25 Kathleen Battista 5-oxazolidin-2-one substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful as orl-1 receptor modulators

Also Published As

Publication number Publication date
PE20081300A1 (es) 2008-09-17
CA2670858C (en) 2015-01-13
US8703948B2 (en) 2014-04-22
CA2670858A1 (en) 2008-06-05
US20080176882A1 (en) 2008-07-24
CN101622254B (zh) 2013-05-29
EP2102206B1 (en) 2015-04-08
WO2008067167A1 (en) 2008-06-05
TW200838862A (en) 2008-10-01
EA200970517A1 (ru) 2009-12-30
MX2009005641A (es) 2009-06-05
CN103202840A (zh) 2013-07-17
CR10898A (es) 2009-10-30
CN101622254A (zh) 2010-01-06
UY30746A1 (es) 2008-05-31
AU2007325355A1 (en) 2008-06-05
JP5727139B2 (ja) 2015-06-03
CL2007003406A1 (es) 2008-08-22
JP2010511054A (ja) 2010-04-08
IL198793A0 (en) 2010-02-17
KR20090083954A (ko) 2009-08-04
AR063982A1 (es) 2009-03-04
ECSP099365A (es) 2009-06-30
EP2102206A1 (en) 2009-09-23
CN103202840B (zh) 2015-02-11

Similar Documents

Publication Publication Date Title
NO20092668L (no) 5-cyano-4-(pyrrolo [2,3B] pyridine-3-yl) -pyrimide derivatives useful as protein kinase inhibitors
NO20085373L (no) P38 inhibitorer, deres fremstilling og anvendelse
EP2526933A3 (en) Inhibitors of bruton's tyrosine kinase
WO2007084557A3 (en) Azaindoles useful as inhibitors of janus kinases
WO2007013896A3 (en) Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors
NO20054359L (no) Cykliske protein tyrosin kinase inhibitorer
MY144293A (en) Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1h-1,2,4-triazol-1-[(phosphonooxy)methyl]-1h-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine
WO2006009755A3 (en) Azaindoles modulating c-kit activity and uses therefor
EP1828181A4 (en) PYRROLO [2,3-B] PYRIDINE-4-YL-AMINE AND PYRROLO [2M3-B] PYRIMIDIN-4-YL-AMINE AS JANUSKINASEINHIBITORS
NO20073628L (no) Pyridoner som er nyttige som inhibitorer av kinaser
CY1108794T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου
PT2332940E (pt) Azaindoles úteis como inibidores de jak e outras proteínas quinases
WO2004078682A3 (en) Cyclic compounds and compositions as protein kinase inhibitors
NO20084747L (no) Tetrahydropteridiner anvendbare som inhibitorer av protein kinaser
NO20090294L (no) Spirocykliske azaindolderivater
NO20082065L (no) Nye imidazo[4,5-b]pyridinderivater som inhibitorer av glykogensyntasekinase 3 for anvendelse ved behandling av demens og neurodegenerative forstyrrelser
WO2006124863A3 (en) Pyrrolopyridine derivatives as protein kinase inhibitors
WO2007022268A3 (en) Compounds and compositions as protein kinase inhibitors
ATE407927T1 (de) 3-phenyl-pyrazol-derivate als modulatoren des zur behandlung damit zusammenhängender störungen nützlichen 5-ht-2a-serotonin-rezeptors
NO20081133L (no) Tieno[2,3-B]-pyridin-5-karbonitriler som protein kinase inhibitorer
NO20080969L (no) 1,2-diarylimidazoler for anvendelse som CBI-modulatorer
GB0327380D0 (en) Method
TW200621721A (en) Methods of preparing indazole compounds
NO20080033L (no) Kinolinderivater som NK3-antagonister
WO2005030151A3 (en) Compounds and compositions as protein kinase inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application